The University of Florida Department of Urology invites you to attend
“Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer:the Return of MVAC”
Charles C. Peyton, MD
Urologic Oncology Fellow
Moffitt Cancer Center
Thursday, May 31, 2018
Department of Urology Conference Room, M2-203C
Review the principles, advantages and disadvantages of neoadjuvant chemotherapy for muscle invasive bladder cancer
Understand the important clinical trials in support of neoadjuvant chemotherapy
Review the key differences and evidence for various neoadjuvant chemotherapy regimens
Highlight emerging data in support of dose-dense or accelerated MVAC prior to radical cystectomy
Urologists, Residents, Nurses, Physician Assistants, and Staff
The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education for physicians.
The University of Florida College of Medicine designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Department of Urology within the University of Florida’s College of Medicine is hosting this free event, which is internally supported.
If you have any questions please feel free to contact Stephanie Stenner at Stephanie.email@example.com.
Dr. Peyton has disclosed that he has no relevant financial relationships. Dr. Vincent Bird, Planning Committee, is a consultant for Boston Scientific. No one else in a position to control content has any financial relationship to disclose.
Section Number: 8119